Akero(US:AKRO)2025-12-02 17:02Summary of Akero Therapeutics Special Meeting Company Overview - Company: Akero Therapeutics (NasdaqGS:AKRO) - Event: Special Meeting of Stockholders - Date: December 2, 2025 Key Points Industry and Company Context - Akero Therapeutics is involved in the biotechnology sector, focusing on developing therapies for liver diseases, particularly non-alcoholic steatohepatitis (NASH) [6][10]. Core Proposals Discussed 1. Merger Proposal: - The primary business discussed was the adoption of the Agreement and Plan of Merger dated October 9, 2025, involving Akero, Novo Nordisk A/S, and NN Invest Sub Incorporated [6]. - The merger will result in Akero becoming a wholly owned subsidiary of Novo Nordisk [6]. 2. Compensation Proposal: - Approval of certain compensation that may be paid to Akero's named executive officers in connection with the merger was also presented [7]. - This proposal was advisory and non-binding [7]. Voting Outcomes - The merger proposal was approved by a majority of the outstanding shares of Akero common stock [9]. - The compensation proposal was also approved by a majority of the outstanding shares [10]. - Due to the approval of the merger proposal, the third proposal regarding the adjournment of the meeting to solicit additional proxies was not presented [10]. Meeting Logistics - The meeting was conducted virtually, allowing stockholders to vote in real-time [4]. - A quorum was established, confirming that the number of shares present constituted a majority of the outstanding shares entitled to vote [5]. Additional Notes - The Inspector of Election was responsible for canvassing the votes and reporting results [3]. - The meeting concluded without any further matters to discuss, and the final report of the Inspector of Election was to be filed with the meeting minutes [10][11].